Xavier Parot
Senior Medical Director ModeX Therapeutics
As a seasoned physician-scientist with extensive experience in global clinical development, regulatory engagement, and strategic leadership, I am passionate about advancing groundbreaking therapies from early research to late-stage clinical execution.
With a track record of designing and executing Phase I-III clinical trials, I have successfully led global development programs across oncology. My expertise spans regulatory interactions (FDA, EMA), cross-functional leadership, and KOL engagement, ensuring scientific excellence and strategic alignment.
Seminars
Wednesday 24th June 2026
Revolutionizing Solid Tumor Care by Applying Haematology‑Driven Insights to Optimize Clinical Delivery and Dosing
5:30 pm
- Extracting key lessons from haematology’s shift in delivery models, including the transition from traditional IV regimens to streamlined subcutaneous approaches, and understanding how these changes have improved patient experience, clinic efficiency, and therapeutic consistency
- Leveraging haematology’s established frameworks for step‑up dosing, toxicity mitigation, and response monitoring, exploring how these principles can be adapted to solid tumor therapies to improve safety, manage CRS and related immune toxicities, and support broader outpatient administration
- Examining real‑world evidence and clinical learnings from haematology agents such as bispecifics and T‑cell engagers, and assessing how these insights are shaping the clinical deployment, exposure management, and dose optimization of emerging solid‑tumor agents, highlighting Tarlatamab and next‑generation molecules as examples of iterative improvement driving enhanced patient outcomes
Wednesday 24th June 2026
Panel Discussion: Leveraging Early Strategies to Mitigate Clinical Toxicity in TCE Therapeutics
12:30 pm
- Exploring design strategies to decouple cytokine production from therapeutic ability to bypass dose-limiting toxicities like CRS without compromising efficacy
- Deep diving into how tumor cells evade detection through antigen escape and the development of next-generation engagers designed to maintain long-term pressure on cold tumors
- Determining the optimal level of antigen expression required for clinical success
Wednesday 24th June 2026
Panel Discussion: Breaking the Efficacy Ceiling with Strategies to Enhance Depth & Durability in Next- Generation T-Cell Engagers
2:30 pm
- Analyzing recent clinical readouts to understand why safety optimized molecules often encounter an efficacy plateau and identifying the biological drivers behind limited therapeutic depth
- Evaluating the integration of signal 2 to overcome the efficacy ceiling, moving from transient T-cell activation to sustained, robust anti-tumor responses
- Utilizing advanced biomarker strategies to identify patientspecific T-cell characterises and TME features that predict which individuals will achieve durable remissions
Wednesday 24th June 2026
Dual-Antigen Targeting & Co-Stimulation to Overcome Resistance & Antigen-Escape in Next Generation Multi- Specifics
2:00 pm
- Translating the success of CD19/CD20 bispecific T-cell engager space by targeting two tumor-associated antigens simultaneously to ensure efficacy event when one antigen is downregulated
- Discussing strategies for incorporating co-stimulatory domains into multi-specific designs to enhance the depth and durability of clinical responses beyond what is possible with CD3 engagement alone
- Addressing the structural hurdles of trispecific and multispecific molecules whilst maintaining manufacturability and acceptable cost of goods
